Skip Navigation

Strength training and ACE I/D genotype in patients with chronic obstructive pulmonary disease (REACT III)

Long Name:Strength training and ACE I/D genotype in patients with chronic obstructive pulmonary disease (REACT III)

The goal of this pilot is to obtain variance and effect size estimates for power calculations in support of a fully powered, randomized clinical trial to examine the effect of ACE genotype on the responses to both endurance and strength training in COPD patients.  Additionally, the proposed pilot will provide important information regarding the physiological mechanisms underlying the changes in physical function following strength training in COPD patients.  The primary aim is to evaluate the feasibility of a 4-month strength training intervention, adherence to the intervention, drop-out from the study and variability in the change in muscle strength measurements among COPD patients recruited by ACE I/D genotype (n=15 II and n=15 DD genotypes).  In addition, the effects of the intervention in both genotype groups on secondary outcomes, including physical function, quadriceps muscle and fat volumes (via computed tomography), body composition (via DXA), skeletal muscle morphology (muscle fiber cross sectional area and fiber type via muscle biopsy), and ACE-mRNA in skeletal muscle will be assessed.


Last Updated: 09-12-2016
Six Wake Forest Baptist Specialties Earn U.S. News RankingsComprehensive Cancer Centers National Designation is Renewed2017-2018 Best DoctorsMagnet Hospital RecognitionJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.

© Wake Forest Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC 27157. All Rights Reserved.